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Abstract
Background: To describe the demographic, clinical, and treatment characteristics of youth diagnosed with juvenile
primary fibromyalgia syndrome (JPFS) who are seen in pediatric rheumatology clinics.
Methods: Information on demographics, symptoms, functioning, and treatments recommended and tried were
obtained on patients with JPFS as part of a multi-site patient registry (the Childhood Arthritis and Rheumatology
Research Alliance Legacy Registry). Data were summarized using descriptive statistics. In a subset of patients completing
registry follow-up visits, changes in symptoms, pain, and functioning were evaluated using growth modeling.
Results: Of the 201 patients with JPFS enrolled in the registry, most were Caucasian/White (85%), non-Hispanic (83%),
and female (84%). Ages ranged from 9 to 20 years (M = 15.4 + 2.2). The most common symptoms reported were
widespread musculoskeletal pain (91%), fatigue (84%), disordered sleep (82%), and headaches (68%). Pain intensity was
rated as moderate to severe (M= 6.3 + 2.4/10). Scores on measures of functioning indicated mild to moderate
impairment, with males observed to report significantly greater impairments. For the 37% of the initial cohort having
follow-up data available, indicators of function and well-being were found to either worsen over time or remain
relatively unchanged.
Conclusions: The symptoms of JPFS remained persistent and disabling for many patients treated by pediatric
rheumatologists. Further study appears warranted to elucidate gender differences in the impact of JPFS symptoms. Work
also is needed to identify accessible and effective outpatient treatment options for JPFS that can be routinely
recommended or implemented by pediatric rheumatology providers.
Keywords: Juvenile fibromyalgia, Pain, Adolescent, CARRA, Registry
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Jennifer.Weiss@hackensackmeridian.org
1Hackensack University Medical Center, 30 Prospect Ave, Hackensack, NJ
07601, USA
Full list of author information is available at the end of the article
Weiss et al. Pediatric Rheumatology           (2019) 17:51 
https://doi.org/10.1186/s12969-019-0356-z
Background
Juvenile primary fibromyalgia syndrome (JPFS) is an
idiopathic chronic pain syndrome thought to affect up
to 6% of children and adolescents [1–4]. Clinical features
of the condition were first described by Yunus and Masi
in 1985 based on a sample of 33 children [5]. JPFS was
characterized at that time as a pediatric condition
primarily comprising widespread musculoskeletal pain,
tender points at soft tissue sites, fatigue, poor sleep,
headaches, paresthesia, and anxiety [5]. Contemporary
understanding of how JPFS manifests has continued to
be derived primarily from small samples of almost exclu-
sively female patients seen in a few practices [2–4].
Criteria for what should constitute a diagnosis of JPFS
also have been debated and variably applied since the
original Yunus and Masi report [2, 6]. Conclusions from
past studies on the impact and outcomes of JPFS there-
fore may not be applicable to the entire spectrum of this
heterogeneous population.
Knowledge about effective treatments for JPFS also re-
mains underdeveloped. As a result, wide practice variations
may exist in how pediatric rheumatologists treat patients
with JPFS. A variety of classes of medications (e.g., opioids,
non-opioid analgesics, anticonvulsants, antidepressants,
muscle relaxants) have been tried for treating symptoms of
JPFS despite limited efficacy studies [7]. Nonpharmacologi-
cal treatments, particularly physical therapies (PT) and
training in cognitive-behavioral pain coping skills, have
more established empirical support for improving symp-
toms and functioning in JPFS [8, 9]. However, these
approaches may not be routinely recommended by
pediatric rheumatologists due to limited awareness and/or
availability.
Improving knowledge about the full spectrum of char-
acteristics and approaches to treatment of JPFS requires
patient data from multiple clinical sites. The Childhood
Arthritis and Rheumatology Research Alliance (CARRA)
Legacy Registry is a prospective observational registry
comprising over 9000 youth with rheumatic disease
across 50 clinical sites. The current study used data from
the CARRA Legacy Registry to: (a) establish the demo-
graphic and symptom characteristics of youth with JPFS
presenting to pediatric rheumatologists; and (b) identify
commonalities and variances in treatment recommenda-
tions for JPFS initiated by pediatric rheumatologists. In a
subset of patients who returned for follow-up visits, we
also sought to determine the extent to which symptoms
and functioning change over time.
Methods
Study design
We conducted a retrospective review of data from the
CARRA Legacy Registry of JPFS patients enrolled be-
tween 2010 and 2014. Eligible patients fulfilled either the
1990 American College of Rheumatology (ACR) [10] or
Yunus and Masi [5] diagnostic criteria for JPFS (depend-
ing on age at time of enrollment), were < 18 years at the
time of symptom onset, and were < 21 years at the time
of enrollment. Study questionnaires were in English.
Children were eligible for enrollment at any time during
their disease course. Written informed consent and
assent (for patients > 9 years old) were obtained for all
subjects.
A general and condition-specific standardized case
report form (CRF) was used across registry sites to uni-
formly collect data on the study measures. Recorded
information was manually entered into a registry data-
base by site research coordinators. These data then were
securely pooled and stored in an i2b2 data warehouse
accessible by approved registry site investigators [11].
The current study was approved by the Institutional
Review Board at Hackensack University Medical Center.
Measures
Baseline visit measures
Patient characteristics Information on self- or parent-
reported demographics (ethnicity, race, sex, and family
household income), diagnosis, date of symptom onset,
and date first seen by a pediatric rheumatologist was re-
corded on standardized CRF at the baseline visit. Patient
anthropometrics were recorded and converted to Body
Mass Index (BMI).
Symptoms Clinicians completed checklists intended
to determine the extent to which common symptoms
of JPFS were present in the month leading up to the
baseline visit. Checklist items included widespread
musculoskeletal pain (bilateral pain locations above
and below the waist), frequent headaches, irritable
bowel symptoms, subjective soft tissue swelling of
the extremities, numbness and tingling of the ex-
tremities, pain modulation with physical activity,
pain modulation with weather changes, pain modula-
tion by anxiety or stress, a comorbid anxiety and/or
depressive disorder, and disordered sleep. If disor-
dered sleep was endorsed, patients were asked to
further specify whether they had non-restorative
sleep, increased sleep latency, hypersomnia, and/or
frequent waking. The presence of hypermobility was
recorded if the patient had a Beighton score > 4 on
physical exam [12]. The Beighton score is a valid in-
strument to evaluate generalized joint mobility in
school–aged children [13].
Past treatments Information was documented on medi-
cations and non-pharmacologic treatments the patient
had tried prior to the initial registry visit. Medications
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were categorized as nonsteroidal anti-inflammatory
drugs (NSAIDs), selective serotonin reuptake inhibitors
(SSRIs), tricyclic antidepressants, serotonin norepinephrine
reuptake inhibitors (SNRIs), gamma-aminobutyric acid
(GABA) analogues, and opioids. Non-pharmacologic treat-
ments queried included PT, herbals/supplements, thera-
peutic massage, meditation, chiropractic, acupuncture/
acupressure, yoga, hypnosis, and craniosacral therapy.
Pain intensity Average pain intensity over the past week
was rated by patients who were at least 10 years of age
using a 0–10 numeric rating scale (NRS) (0 = “no pain”
and 10 = “very severe pain”). The NRS is a well-estab-
lished measure for pediatric populations [14]. Parent
proxy reports (using a 0–10 NRS) were obtained in chil-
dren under 10 years of age.
Functional ability and health-related quality of life
The Childhood Health Assessment Questionnaire (CHAQ)
was completed by patients (or caregiver proxies if patients
were less than 10 years of age) as a measure of the impact
of fibromyalgia on daily functioning [15]. This question-
naire includes questions about functional ability over the
past week across eight categories: dressing, grooming, aris-
ing, eating, walking, hygiene, reach, and grip. Item scores
range from 0 to 3 and are averaged to form a total “Disabil-
ity Index” score (ranging from 0 to 3), with higher scores
indicating greater functional disability.
Patients (10 years or older) or caregivers also com-
pleted two global ratings pertaining to the patient’s
health status [16]. On the first, patients/caregivers were
asked to consider the ways their/their child’s condition
affects them and rate on a 0–10 scale (“very well” to
“very poor”) how the patient is doing, with higher
numbers indicating poorer well-being. On the other, pa-
tients/caregivers were asked to rate the patient’s overall
health-related quality of life (HRQOL) on a 5-point scale
(“excellent” to “very poor”), with higher scores indicating
poorer health-related quality of life. In addition, the
patients’ functional ability was assessed using the ACR
functional class rating. This measure is a physician rat-
ing of the patient’s functioning on a 1–4 scale ranging
from “able to perform usual activities of daily living” to
“limited in ability to perform usual self-care, vocational,
and avocational activities.” [17]
Recommended treatments Treatments recommended
or provided at the baseline visit by a pediatric rheumatolo-
gist were documented by the clinician/research nurse on a
CRF. Choices appearing on the form included the follow-
ing: psychoeducation about chronic pain, sleep hygiene
education, graduated aerobic exercise, medications for
pain, PT, general counseling, cognitive-behavioral therapy
(CBT), biofeedback-assisted relaxation training, and other
specialty referral (including psychiatry, pain clinic, re-
habilitation clinic, or integrative medicine clinic).
Follow-up measures
For patients completing the baseline visit and returning
for a follow-up visit, the checklists of disease symptoms,
pain intensity rating, and functioning and quality of life
measures were repeated to gauge stability of these
variables over time. Patient adherence to treatment
recommendations was also documented, along with rea-
sons for the patient/family not pursuing recommenda-
tions if applicable (i.e., service not available, not covered
by insurance, patient/family disinterest, or “other”).
Statistical analyses
Descriptive statistics (frequency counts and estimates of
central tendency and variability as applicable) were used to
summarize data from the baseline visit on patient demo-
graphics, symptoms, pain intensity, indices of functioning
and well-being, and treatments tried and recommended.
Age and sex differences in symptoms, treatments, and the
indices of functioning and well-being were explored using
point-biserial correlations (rbs), chi-square analyses (χ
2), or
independent samples t-tests as applicable. SPSS® software
(IBM) version 24.0 was used for these analyses.
To evaluate changes in symptoms and functioning fol-
lowing the baseline visit, multilevel growth modeling
using HLM version 7.0 (Scientific Software International
Inc.) was used. Only those in the sample with at least one
follow-up visit were included in these analyses. In these
models, time elapse since the baseline visit was specified
as a predictor of changes in endorsed symptoms, pain in-
tensity, and scores/ratings on the functioning and well-be-
ing indices. For the dependent variables that were coded
as binary (i.e., presence of a given symptom), a logistic
model was specified with a Poisson distribution and logit
link function [18]. Significant positive values for the esti-
mated time coefficient from these models indicate a reli-
able increase in the likelihood of the item being endorsed
(for symptoms) or increased impairment in the function-
ing and well-being indices; significant negative values for
the time coefficient indicate the opposite. Age, sex, symp-
tom duration, and self-reported adherence to initial rec-
ommendations were evaluated as moderators of changes
over time in these variables. We found no significant con-
cerns emerged regarding model misfit based on the model
specifications we used.
Results
Patient and condition characteristics
Table 1 provides summary information on patient
characteristics and symptoms reported at the base-
line visit. Data were available from 201 patients (33
males) with JPFS enrolled across 23 unique clinical
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sites. Ages at the baseline visit ranged from 9 to 20 years
(mean = 15.4, SD = 2.2). Most patients identified as Cauca-
sian/White (85%) and non-Hispanic (83%). Reported
annual household income was fairly evenly distributed
across categories (median = $75-100 K/year). All patients
except one reported having health insurance. Patient BMIs
recorded at the baseline visit ranged from 13.6 to 50.6
(mean = 24.2, SD = 6.1). Patients reported being symptom-
atic for a mean of 1.7 years (SD = 2.2 years; range 0–11.8
years) prior to their first visit to a pediatric rheumatolo-
gist. Thirty-six patients (18%) endorsed having a family
history of fibromyalgia. Greater household income was
associated with less time elapse between reported initial
symptom onset and evaluation with a pediatric rheuma-
tologist (r = −.21, p = .01); no other demographic variables
were significantly associated with this time elapse.
The most commonly reported symptoms endorsed by
patients at the baseline visit included widespread muscu-
loskeletal pain (91%), fatigue (84%), disordered sleep
(82%), and headaches (68%). Most patients also reported
pain modulation by stress (80%), physical activity (75%),
and weather changes (61%). There were no significant
age or sex differences in symptoms endorsed except for
numbness/tingling, which was more often endorsed in
females than males (36% versus 13% respectively,
χ2 = 5.09, p = 0.03).
Sixty-six patients (37% of the initial sample of the JPFS
cohort in the registry) returned for a follow-up visit with
their pediatric rheumatologist between 0.2 to 2.5 years
from the baseline visit (mean = 0.9, SD = 0.5 years). The
number of follow-up visits available during the time
period sampled ranged from 1 (68% of the follow-up
sample) to 5 (2% of the follow-up sample). Of the fol-
low-up sample, 82% of patients were female and ranged
in age from 9 to 21 years (mean = 15.0, SD = 2.28 years).
There were no significant differences in known demo-
graphic characteristics between those in the initial co-
hort who did and did not return for follow-up visits.
Previous treatments
Table 2 lists treatments tried as reported at the baseline
visit. For pharmacological treatments, 39% of the sample
reported no prior use at all, 38% reported prior use of
one medication type, and 23% reported trials of at least
two medication types. The most common medication
previously tried was NSAIDs (27%). The least common
medication tried was opioids (4%). There was no rela-
tionship of age with prior use of any of the medication
categories. The only sex difference was that a higher
proportion of males reported using a GABA agonist
(26% versus 8%, χ2 = 7.95, p < 0.01).
About two-thirds (67%) of patients reported no
prior use of any of the listed non-pharmacologic op-
tions. The most common non-pharmacologic treat-
ment tried was PT (21%), and the least common was
craniosacral therapy (two patients). Increasing age
was modestly but reliably associated with reported
Table 1 Baseline demographic and clinical characteristics of
patients with juvenile primary fibromyalgia syndrome in the
CARRA Legacy Registry
Variable Value
Age in years at diagnosis (Mean ± SD) 15.4 ± 2.2
Sex (n, %)
Male 33 (16%)
Female 168 (84%)
Race (n, %)
White 171 (85%)
Black/African-American 15 (8%)
American Indian or Alaskan Native 1 (1%)
Asian 4 (2%)
Mixed race 5 (2%)
Other 5 (2%)
Ethnicity (n, %)
Not Hispanic 167 (83%)
Hispanic 34 (17%)
Annual household income (n, valid %)
< $25,000 23 (15%)
$25–$49,999 18 (12%)
$50–$74,999 29 (19%)
$75–$99,999 22 (14%)
$100–$150,000 34 (22%)
> $150,000 30 (19%)
Unknown/missing 45
Body Mass Index (Mean ± SD) 24.2 ± 6.1
Symptom duration in years prior to diagnosis (Mean ± SD) 1.7 ± 2.1
Symptoms endorsed for past month
Widespread musculoskeletal pain 164 (91%)
Pain modulation with anxiety or stress 121 (80%)
Pain modulation with physical activity 117 (75%)
Frequent headaches 111 (68%)
Pain modulation with weather change 86 (61%)
Nonrestorative sleep 94 (52%)
Frequent awakenings 75 (42%)
Increased sleep latency 74 (41%)
Numbness and tingling of extremities 48 (32%)
Anxiety and/or depression 40 (28%)
Hypermobility on exam 35 (28%)
Subjective soft tissue swelling of extremities 32 (22%)
Irritable bowel symptoms 24 (16%)
Hypersomnia 25 (14%)
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use of some of the non-pharmacologic strategies, in-
cluding meditation (rpb = .20, p < .01), hypnosis
(rpb = .17, p = .03), and yoga (rpb = .19, p = .01). The
only significant sex difference observed was that
males proportionately more often reported use of
herbal remedies than females (22% versus 7%, χ2 =
6.06, p = .01).
Initial pain and functional status
Pain scores at the baseline visit on average were in the
moderate to severe range (mean = 6.3/10, SD = 2.4). Pain
ratings did not significantly differ by sex or age. Scores
on the functional disability and well-being measures
were broad in range but on average indicated mild to
moderate impairment (mean for CHAQ = .77, SD = .57;
mean for subjective well-being rating = 5.1, SD = 2.2;
mean for global rating of HRQOL = 3.0, SD = .84;
median for current ACR class = Class 2). There were no
age differences on the functioning and well-being mea-
sures. Males were found to be reliably more disabled
than females based on the CHAQ measure (1.02 versus
.70, t (199) = 4.12, p < .01). Males were also found to
have worse HRQOL when compared to females (3.3
versus 2.9, t (194) = 2.01, p = .04).
Treatments recommended
Table 2 also lists treatments recommended by rheuma-
tologists at the baseline visit. In almost all cases (92%),
providers reported doing education about chronic pain.
Education on sleep hygiene and recommendations to
begin a graduated aerobic exercise program also were
common (70 and 76% of patients, respectively). For
about half of patients (51%), medications were recom-
mended. The most common referrals made included a
referral to physical therapy (57% of patients), to general
counseling (53% of patients), and to a pediatric or
general pain clinic (46% of patients); patients were rarely
referred to psychiatry (4%), integrative medicine (3%), or
rehabilitation (1%). Only a minority of patients referred
for outside services returned for follow-up with the
rheumatologist during the study time period (36% of
pain clinic referrals, 36% of counseling referrals, 26% of
PT referrals, and 25% of CBT referrals).
Treatments pursued
Of the 66 patients returning for follow-up visits during
the study period, the majority (68%) of patients/parents
reported doing most or all of the treatments recom-
mended from the baseline visit; 28% reported doing
some of the recommended treatments, and 4% reported
doing none of the recommended treatments. The most
common reasons for not pursuing the recommended
treatment(s) included disinterest (16%), insurance failing
to cover the treatment (8%), and the treatment not being
available in the patient’s area (2%).
Changes in symptoms and functional status over time
There was a reduced likelihood of reporting widespread
pain over time since the baseline visit (b = − 0.57 ± 0.22,
t (91) = − 2.53, p = 0.01). Otherwise, symptoms reported
at the baseline visit remained relatively constant over
time. Indicators of function and well-being were found
to either worsen over time since the baseline visit (for
CHAQ: b = 10 ± 0.05, t (91) = 2.05, p = 0.04; for subject-
ive well-being: b = 0.65 ± 0.25, t (91) = 2.61, p = .01) or
remain relatively consistent (for HRQOL: b = .05 ± 0.09,
t (91) = 0.53, p = .59). Duration of symptoms prior to the
first rheumatologist visit did not significantly moderate
these results. Whether or not patients reported following
Table 2 Treatments tried and recommended for juvenile
primary fibromyalgia syndrome patients
Treatments % of sample
Pharmacological treatments previously tried
Daily non-steroidal anti-inflammatory drugs 27%
Selective serotonin reuptake inhibitors 17%
Tri-cyclic antidepressants 17%
Gamma-aminobutyric acid analogues 11%
Selective norepinephrine reuptake inhibitors 5%
Opioids 4%
Non-pharmacological treatments previously tried
Physical therapy 21%
Herbals and supplements 9%
Therapeutic massage 16%
Mindfulness/meditation 12%
Chiropractic 6%
Acupuncture/acupressure 5%
Yoga 4%
Hypnosis 2%
Craniosacral therapy 1%
Treatments recommended or provided at baseline visit
Psychoeducation on chronic pain 92%
Graduated aerobic exercise program 76%
Sleep hygiene education 70%
Physical therapy referral 57%
General counseling referral 53%
Medications 51%
Referral to pain clinic 46%
Cognitive-behavioral therapy referral 42%
Biofeedback referral 8%
Referral for psychiatric evaluation 4%
Referral for integrative medicine evaluation 3%
Referral to rehabilitation clinic 1%
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initial treatment recommendations also did not moder-
ate these findings. Worsening of subjective well-being
over time was found to be even more pronounced in
male patients (b = .1.53 ± 0.58, t (90) = 2.63, p = ..01.
There were no other significant age or sex differences in
changes in symptoms and functioning over time.
Discussion
We sought to determine the demographic, clinical, and
treatment characteristics of a representative sample of
youth with JPFS patients who seek evaluation and
treatment at pediatric rheumatology centers in North
America. By virtue of using patient data from a registry
in which multiple clinical sites participated, results of
this study are thought to be relatively representative and
generalizable to clinical samples of JPFS patients.
The majority of the JPFS patients in the registry cohort
were White, non-Hispanic, adolescent females. These
characteristics are similar to those observed in all studies
of youth with juvenile fibromyalgia to date [2, 3, 5, 8, 19].
This may reflect demographic variation in family prefer-
ences and responses to symptoms of JPFS. Specifically,
certain subgroups of patients with JPFS symptoms (e.g.,
ethnic minorities) may be less likely to seek treatment, or
they may seek treatments in places not sampled by
current studies. The demographic characteristics of this
study population as well as other reported JPFS popula-
tions alternatively may suggest predisposing biological
and/or environmental factors that are unique to this group
[2]. Despite the typical disproportionate representation
of females in the study sample, however, our male
subsample was up to fivefold larger than that of other
studies of youth with JPFS. Thus, this study allowed
for some unique provisional comparisons by sex in
the characteristics and treatment of JPFS.
Results from the current study indicate that pain in
youth with JPFS is generally rated as moderate to severe
in intensity. Stress, physical activity, and weather were
identified by the majority of patients as exacerbating
pain. Other symptoms found to be most frequently re-
ported included fatigue, disordered sleep, and headaches.
Conversely, symptoms more rarely endorsed (reported
by less than one-third of the sample) included hypermo-
bility, subjective soft tissue swelling, and IBS. Symptoms
were found to be associated with moderate and enduring
levels of impairment in functioning and well-being. The
phenotypic characteristics observed in this study are
largely consistent with data from other studies. In
particular, pain scores from the current study (M =
6.3 ± 2.4/10) were comparable to, or slightly higher than,
those reported in other studies of JPFS [8, 19]. General-
ized aches, headaches and sleep disturbance were also
found to be the most commonly reported symptoms (>
70%) in another cohort study [20], although relatively
few patients in that study reported fatigue (20%, versus
84% in the current study). Most research on youth with
JPFS has similarly found enduring moderate to severe
functional impairment [19]. Results of our study there-
fore corroborate previous studies in their description of
common presenting characteristics of patients with JPFS.
Few sex differences were observed in these common
presenting symptoms. However, males with JPFS re-
ported higher levels of impairment in functioning and
well-being. To our knowledge this has not been previ-
ously reported. This finding may have implications for
the importance of recognition and diagnosis of JPFS
symptoms in males presenting to pediatric rheumatology
clinics.
Patients with JPFS reported about an 18month time
elapse on average between onset of symptoms and initial
rheumatology evaluation. Other studies similarly have
reported that symptoms may be present for many
months prior to a correct diagnosis of JPFS [20, 21].
However, results of the current study were based on a
multinational sample and 23 clinical sites. Thus, the
observed delay in being evaluated in rheumatology is un-
likely to be solely a reflection of barriers or trends that
are peculiar to a particular site or region. During the
waiting period, patients may see multiple providers and
receive many tests or potentially risky or contraindicated
treatment recommendations before receiving a diagnosis
of JFPS. Data on prior treatments from the current study
did suggest that a minority of patients had tried treat-
ments with unknown or questionable efficacy (e.g., daily
NSAIDs, opioids, chiropractic manipulation), whereas
the majority had not yet been treated at all. Pain and
functional limitations recently have been found to in-
crease with a longer delay between symptom onset and
appropriate diagnosis [22]. These findings collectively
suggest that early identification and diagnosis is a critical
unmet need for JPFS, one likely requiring optimized
classification criteria and education of those providers
most likely to first encounter these patients.
Treatments recommended or implemented in pediatric
rheumatology for patients with JPFS were partly consist-
ent with evidence-based care [23]. We are unable to deter-
mine from this study, however, the quality of the
recommendations, education, and referrals provided. The
most commonly prescribed or implemented interventions
by pediatric rheumatologists based on this study included
education on chronic pain, graduated aerobic exercise,
sleep hygiene education, PT, and counseling. Aerobic and
strength training exercises have evidence of being a safe
and effective treatment for fibromyalgia symptoms [9].
Although the efficacy of general counseling for youth with
fibromyalgia is unstudied, cognitive-behavioral therapy
(CBT) has an established evidence base [8]. In the case of
PT and CBT, however, motivation to participate may be
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low and result in poor follow-through and adherence,
which in turn may impede symptom improvement. In the
case of CBT for pain management, there may also be
limited access to qualified providers to implement this
treatment, and it is not yet known if remote options (e.g.,
telehealth, mobile applications) are equally efficacious re-
placements [24]. The majority of patients in the current
study who returned for follow-up visits self-reported that
they had followed most or all treatment recommenda-
tions, albeit we could not confirm the accuracy of these
reports. Those reporting they did not follow recommenda-
tions, however, indicated motivation/interest as the
primary barrier rather than access problems.
For about half of patients, pediatric rheumatologists
also reported starting or changing medications. Al-
though some medications (duloxetine, milnacipran,
pregablin) are Federal Drug Administration (FDA) ap-
proved for treating fibromyalgia in adults, there are no
FDA-approved medications for the treatment of JPFS.
There also is weak agreement [25] on the benefits of
medications prescribed off-label for fibromyalgia symp-
toms [7, 23]. Taken together, our study results suggest
that pediatric rheumatology providers may benefit from
collaborative efforts that help them recognize and treat
JPFS using evidence-based, easily accessible, and prac-
tical treatment strategies. Historically such education
has been minimally available during medical training
[26]. Pediatric rheumatology fellowships should also
consider increasing their focus on training in pharmaco-
logic and non-pharmacologic pain management.
Results of this study should be interpreted with con-
sideration of known limitations. Patients enrolled in the
registry were seeking treatment in pediatric rheumatol-
ogy, were able to speak and read English, and were
enrolled by a subset of the total sites involved in the
overall CARRA Legacy Registry. Thus, the resulting
sample still may not be entirely reflective of the general
population of youth with JPFS. Additionally, only about
one-third of the baseline sample returned to contribute
data at follow-up visits. The patients who returned for
follow-up visits may be those whose symptoms are most
refractory to treatment. If this were the case, the ob-
served maintenance or worsening of symptoms and poor
functioning over time may not accurately reflect trajec-
tories of most patients.
Measures used to evaluate pain, functioning and well-
being in the CARRA Legacy Registry also were selected
for use across conditions seen in pediatric rheumatology.
Although beneficial for cross-condition comparisons,
some measures have less known specificity and utility
for chronic pain. For example, whereas the Childhood
Health Assessment Questionnaire is sensitive to the self-
care and fine motor difficulties that can be common in
other pediatric rheumatic diseases, it may not fully
capture the range of physical, psychosocial, and aca-
demic impairments for youth with JPFS. Relatedly, a sin-
gle measure of pain (pain intensity) was pragmatic to
implement to quantify pain across conditions but does
not fully reflect the features and dynamics of pain in
JPFS. Use of other patient-reported outcome measures
more commonly used in pediatric chronic pain studies
to quantify pain and functional limitations, such as pain
diaries and the Functional Disability Inventory, [27]
may have produced different and more comprehensive
findings.
Conclusions
Overall, the current study further establishes that the
main symptoms of JPFS are persistent and moderately
disabling for many youth, with a subset of patients
having minimal improvement despite at least some
components of evidence-based care being implemented
in pediatric rheumatology. Future research suggested by
the study results should further explore gender differences
among patients with JFPS, identification of barriers to
timely diagnosis and treatment, and identification of ef-
fective treatment options to implement in the practice of
pediatric rheumatology.
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